FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100083413> ?p ?o ?g. }

• W2100083413 endingPage "3352" @default.
• W2100083413 startingPage "3338" @default.
• W2100083413 abstract "The identification of the thrombin receptor has promoted the interest for the development of new therapeutic agents capable of selectively inhibiting unwanted biological effects of thrombin on various cell types. In this study we have designed and synthesized two series of new thrombin receptor antagonists based on the thrombin receptor motif sequence S42FLLR46, one possessing two (Phe/Arg) pharmacophoric groups and the other possessing three (Phe/Arg/NH2). N-(6-Guanidohexanoyl)-N'-(phenylacetyl)piperazine (1), N-(phenylacetyl)-4-(6-guanidohexanoylamidomethyl)piperidine (2), and N-(phenylacetyl)-3-(6-guanidohexanoylamido)pyrrolidine (3) (group A) carry the two pharmacophoric side chains of Phe and Arg residues incorporated on three different templates (piperazine, 4-aminomethylpiperidine, and 3-aminopyrrolidine). Compounds with three pharmacophoric groups (group B) were built similarly to group A using the same templates with the addition of an extra methylamino group leading to (S)-N-(6-guanidohexanoyl)-N'-(2-amino-3-phenylpropionyl)piperazine (4), (S)-N-(2-amino-3-phenylpropionyl)-4-(6-guanidohexanoylamidomethyl)piperidine (5), and (S)-N-(2-amino-3-phenylpropionyl)-3-(6-guanidohexanoylamido)pyrrolidine (6). Compounds were able to inhibit thrombin-induced human platelet activation even at low concentrations. In particular, among compounds in group A, compound 3 was found to be the most powerful thrombin receptor activation inhibitor, showing an IC50 of approximately 0.11 mM on platelet aggregation assay. Among compounds in group B, compound 4 was the most powerful to inhibit thrombin-induced platelet aggregation, showing an IC50 of approximately 0.09 mM. All compounds were also found to act as agonists in the rat aorta relaxation assay. Interestingly, the order of potency of these compounds as agonists of the endothelial thrombin receptor was the inverse of the order of potency of the same compounds as antagonists of the platelet thrombin receptor. Such compounds that are causing vasodilation while simultaneously inhibiting platelet aggregation would be very useful in preventing the installation of atherosclerotic lesions and deserve further investigation as potential drugs for treating cardiovascular diseases. The above findings coupled with computational analysis molecular dynamics experiments support also our hypothesis that a cluster of phenyl, guanidino, and amino groups is responsible for thrombin receptor triggering and activation." @default.
• W2100083413 created "2016-06-24" @default.
• W2100083413 creator A5000372948 @default.
• W2100083413 creator A5009553458 @default.
• W2100083413 creator A5032749978 @default.
• W2100083413 creator A5048160310 @default.
• W2100083413 creator A5053153114 @default.
• W2100083413 creator A5054817512 @default.
• W2100083413 creator A5057892922 @default.
• W2100083413 creator A5061997157 @default.
• W2100083413 creator A5072960254 @default.
• W2100083413 creator A5076188669 @default.
• W2100083413 date "2004-05-19" @default.
• W2100083413 modified "2023-09-26" @default.
• W2100083413 title "Design and Synthesis of Novel Biologically Active Thrombin Receptor Non-Peptide Mimetics Based on the Pharmacophoric Cluster Phe/Arg/NH₂ of the Ser₄₂-Phe-Leu-Leu-Arg₄₆ Motif Sequence: Platelet Aggregation and Relaxant Activities" @default.
• W2100083413 cites W1487725726 @default.
• W2100083413 cites W1489529085 @default.
• W2100083413 cites W1495307817 @default.
• W2100083413 cites W1668651547 @default.
• W2100083413 cites W1774746154 @default.
• W2100083413 cites W1987934518 @default.
• W2100083413 cites W1990500910 @default.
• W2100083413 cites W1996052275 @default.
• W2100083413 cites W1997447387 @default.
• W2100083413 cites W1998899308 @default.
• W2100083413 cites W2001285955 @default.
• W2100083413 cites W2015451804 @default.
• W2100083413 cites W2016969337 @default.
• W2100083413 cites W2021565138 @default.
• W2100083413 cites W2032822608 @default.
• W2100083413 cites W2033629898 @default.
• W2100083413 cites W2036468924 @default.
• W2100083413 cites W2042402586 @default.
• W2100083413 cites W2069828003 @default.
• W2100083413 cites W2072197344 @default.
• W2100083413 cites W2093175816 @default.
• W2100083413 cites W2094026324 @default.
• W2100083413 cites W2095481288 @default.
• W2100083413 cites W2165453706 @default.
• W2100083413 cites W2166170833 @default.
• W2100083413 cites W228010362 @default.
• W2100083413 cites W3128827104 @default.
• W2100083413 cites W4244048148 @default.
• W2100083413 cites W4254668683 @default.
• W2100083413 doi "https://doi.org/10.1021/jm031080v" @default.
• W2100083413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15189031" @default.
• W2100083413 hasPublicationYear "2004" @default.
• W2100083413 type Work @default.
• W2100083413 sameAs 2100083413 @default.
• W2100083413 citedByCount "9" @default.
• W2100083413 countsByYear W21000834132012 @default.
• W2100083413 crossrefType "journal-article" @default.
• W2100083413 hasAuthorship W2100083413A5000372948 @default.
• W2100083413 hasAuthorship W2100083413A5009553458 @default.
• W2100083413 hasAuthorship W2100083413A5032749978 @default.
• W2100083413 hasAuthorship W2100083413A5048160310 @default.
• W2100083413 hasAuthorship W2100083413A5053153114 @default.
• W2100083413 hasAuthorship W2100083413A5054817512 @default.
• W2100083413 hasAuthorship W2100083413A5057892922 @default.
• W2100083413 hasAuthorship W2100083413A5061997157 @default.
• W2100083413 hasAuthorship W2100083413A5072960254 @default.
• W2100083413 hasAuthorship W2100083413A5076188669 @default.
• W2100083413 hasConcept C114373084 @default.
• W2100083413 hasConcept C116073593 @default.
• W2100083413 hasConcept C170493617 @default.
• W2100083413 hasConcept C178790620 @default.
• W2100083413 hasConcept C185592680 @default.
• W2100083413 hasConcept C202751555 @default.
• W2100083413 hasConcept C203014093 @default.
• W2100083413 hasConcept C2776201271 @default.
• W2100083413 hasConcept C2777292125 @default.
• W2100083413 hasConcept C2777752497 @default.
• W2100083413 hasConcept C2778851528 @default.
• W2100083413 hasConcept C2778886182 @default.
• W2100083413 hasConcept C2779281246 @default.
• W2100083413 hasConcept C2781462491 @default.
• W2100083413 hasConcept C55493867 @default.
• W2100083413 hasConcept C57002609 @default.
• W2100083413 hasConcept C71240020 @default.
• W2100083413 hasConcept C86803240 @default.
• W2100083413 hasConcept C89560881 @default.
• W2100083413 hasConceptScore W2100083413C114373084 @default.
• W2100083413 hasConceptScore W2100083413C116073593 @default.
• W2100083413 hasConceptScore W2100083413C170493617 @default.
• W2100083413 hasConceptScore W2100083413C178790620 @default.
• W2100083413 hasConceptScore W2100083413C185592680 @default.
• W2100083413 hasConceptScore W2100083413C202751555 @default.
• W2100083413 hasConceptScore W2100083413C203014093 @default.
• W2100083413 hasConceptScore W2100083413C2776201271 @default.
• W2100083413 hasConceptScore W2100083413C2777292125 @default.
• W2100083413 hasConceptScore W2100083413C2777752497 @default.
• W2100083413 hasConceptScore W2100083413C2778851528 @default.
• W2100083413 hasConceptScore W2100083413C2778886182 @default.
• W2100083413 hasConceptScore W2100083413C2779281246 @default.
• W2100083413 hasConceptScore W2100083413C2781462491 @default.
• W2100083413 hasConceptScore W2100083413C55493867 @default.
• W2100083413 hasConceptScore W2100083413C57002609 @default.
• W2100083413 hasConceptScore W2100083413C71240020 @default.

• next